Inhibikase Therapeutics Stock Fundamentals
| IKT Stock | USD 2.73 0.37 15.68% |
Inhibikase Therapeutics fundamentals help investors to digest information that contributes to Inhibikase Therapeutics' financial success or failures. It also enables traders to predict the movement of Inhibikase Stock. The fundamental analysis module provides a way to measure Inhibikase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibikase Therapeutics stock.
At this time, Inhibikase Therapeutics' Interest Expense is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 935.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 5.3 M in 2024. Inhibikase | Select Account or Indicator |
Inhibikase Therapeutics Company Operating Margin Analysis
Inhibikase Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Inhibikase Therapeutics Operating Margin | (238.85) % |
Most of Inhibikase Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibikase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Inhibikase Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Inhibikase Therapeutics has an Operating Margin of -238.8505%. This is much higher than that of the Biotechnology sector and 113.13% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Inhibikase Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Inhibikase Therapeutics's current stock value. Our valuation model uses many indicators to compare Inhibikase Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibikase Therapeutics competition to find correlations between indicators driving Inhibikase Therapeutics's intrinsic value. More Info.Inhibikase Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Inhibikase Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Inhibikase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Inhibikase Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibikase Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics of similar companies.Inhibikase Therapeutics is currently under evaluation in operating margin category among its peers.
Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Inhibikase Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 180.34 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 305.66 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 2,305 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 183.44 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.7 M | 1.5 M | |
| Total Revenue | 260.5 K | 247.5 K | |
| Cost Of Revenue | 13.6 M | 14.3 M | |
| Stock Based Compensation To Revenue | 1.92 | 2.02 | |
| Sales General And Administrative To Revenue | 0.56 | 0.50 | |
| Research And Ddevelopement To Revenue | 52.28 | 54.89 | |
| Capex To Revenue | 0.05 | 0.05 | |
| Revenue Per Share | 0.05 | 0.05 | |
| Ebit Per Revenue | (77.12) | (73.26) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.